Aldevron News

Aldevron, Nature Technology Corporation team up to offer Nanoplasmids™ for gene therapy manufacturing

Aldevron has announced the immediate availability of NanoplasmidsTM and antibiotic-free RNA-OUT technology for use in gene therapy manufacturing. Through a license agreement with Nature Technology Corporation (NTC), Aldevron can now provide its clients the option of using NTC’s plasmid technology to provide a more efficient system for manufacturing viral vectors used in gene and cell therapy.

Read More

Aldevron announces GMP gene synthesis service to support neoantigen-based oncology research and other applications

Aldevron has added GMP gene synthesis to its array of services. This expanded capability will be used primarily to support Aldevron’s clients who require rapid GMP gene synthesis for novel cancer treatments based on neoantigens. The company noted the service is not suited for routine, research-grade synthesis, for which Aldevron will continue using outside providers.  

Read More

Forum Report: Aldevron's expansion could equate to $500 million for region

News report courtesy Forum Communication, written by Barry Amundson. Published August 29, 2019

Tax incentive supporters are putting the pressure on to show that programs being offered to businesses and developers are not only going to eventually provide impressive property tax payments but also provide positive ripple effects in the community.

Read More

Aldevron Breaks Ground on 14-Acre Campus Expansion

Fargo, N.D., based company increasing capacity to better serve
rapidly growing biotech industry

Aldevron officially broke ground on its 14-acre campus expansion at its global headquarters in Fargo, North Dakota, August 19. Three buildings are planned, with construction of its next GMP manufacturing facility starting first.

Read More

Genprex™ Manufacturing Partner Aldevron Completes Significant Step in Manufacturing for Oncoprex™ Clinical Development Program

Newly manufactured plasmids will be used in clinical trials evaluating Oncoprex™ in combination with targeted therapies and immunotherapies

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, announced that its manufacturing partner, Aldevron, has successfully completed the manufacturing of the TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA pursuant to the manufacturing agreement between Genprex and Aldevron that was announced in September 2018.

Read More

Aldevron now utilizing Berkeley Lights' Beacon® platform

Aldevron, a global leader in antibody discovery to the biotech industry, announced today the acquisition and installation of the Beacon Optofluidic platform (Beacon) to support rapid execution of species agnostic single B-cell antibody discovery to complement its industry-leading genetic immunization and hybridoma capabilities.

The Beacon platform will be located in the recently announced expansion lab space in Aldevron’s Freiburg, Germany, facility and will be coming on-line in June 2019. Aldevron is the first CRO in Germany to adapt this new technology for antibody discovery.

Read More